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Abstract
The aim of this work was to use phosphorus magnetic resonance spectroscopy (31P MRS) to investigate the phar-
macodynamic effects of LAQ824, a histone deacetylase (HDAC) inhibitor. Human HT29 colon carcinoma cells
were examined by 31P MRS after treatment with LAQ824 and another HDAC inhibitor, suberoylanilide hydroxamic
acid. HT29 xenografts and tumor extracts were also examined using 31P MRS, pre– and post–LAQ824 treatment.
Histone H3 acetylation was determined using Western blot analysis, and tumor microvessel density by immuno-
histochemical staining of CD31. Phosphocholine showed a significant increase in HT29 cells after treatment with
LAQ824 and suberoylanilide hydroxamic acid. In vivo, the ratio of phosphomonoester/total phosphorus (TotP) sig-
nal was significantly increased in LAQ824-treated HT29 xenografts, and this ratio was inversely correlated with
changes in tumor volume. Statistically significant decreases in intracellular pH, β-nucleoside triphosphate
(β-NTP)/TotP, and β-NTP/inorganic phosphate (Pi) and an increase in Pi/TotP were also seen in LAQ824-treated
tumors. Tumor extracts showed many significant metabolic changes after LAQ824 treatment, in parallel with in-
creased histone acetylation and decreased microvessel density. Treatment with LAQ824 resulted in altered phos-
pholipid metabolism and compromised tumor bioenergetics. The phosphocholine and phosphomonoester
increases may have the potential to act as pharmacodynamic markers for noninvasively monitoring tumor re-
sponse after treatment with LAQ824 or other HDAC inhibitors.
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Introduction
DNA is packaged into chromatin in eukaryotic cells. The functional
and structural properties of chromatin can be influenced by various
posttranslation modifications of the amino-terminal tails of nucleoso-
mal histones. Histone acetylation plays an important role in the regu-
lation of transcription, replication, and DNA repair [1–3]. Acetylation
is regulated by the opposing effects of two families of enzymes, histone
acetyltransferases and histone deacetylases (HDACs). Histone acetyl-
transferases catalyze the addition of acetyl groups, whereas HDACs
catalyze the reverse reaction. Previous studies have found evidence that
aberrant recruitment of HDACs may cause specific changes in gene
expression profiles in transformed cells [4–7]. Deregulation of histone
acetylation has also been associated with the development of various
human cancers [4–7].
Inhibition of HDAC causes modification of chromatin structure
and results in activation (e.g., p53, p21, and caspases) and deactiva-
tion [e.g., hypoxia-inducible factor 1 alpha (HIF-1α) and vascular
endothelial growth factor (VEGF)] of a variety of genes that mediate
proliferation, cell cycle progression, angiogenesis, and apoptosis [7–
19]. In addition to their effect on histones, certain HDAC inhibitors
also interact directly with various proteins whose function is modi-
fied by acetylation. These include some transcription factors (e.g.,
E2F-1 and NF-κB), several signal transduction mediators (e.g.,
pRB), and the heat shock protein 90 (Hsp90), a molecular chaperone
that maintains the stability and maturation of several oncoproteins,
including C-RAF, AKT, and ErbB2 [19–24]. Thus, inhibition of
HDAC is expected to impact on the activation of several oncogenic
and survival-related pathways.
The HDAC inhibitor, LAQ824, is effective against several human
tumor models [13,22–26]. LAQ824 inhibits VEGF-induced angio-
genesis, causes cell cycle arrest, and induces apoptosis in human can-
cer cells and xenograft models [13,22–26].
The rational development of new molecular cancer therapeutics re-
quires the discovery and validation of biomarkers of drug action [27–
29]. These are valuable because they can provide proof of concept for
the intended mechanism of action in phase I clinical studies and aid in
dose selection for phase II trials. A recent study has shown that, in the
majority of phase I trial designs for the investigation of targeted, non-
cytotoxic agents in solid tumors, traditional endpoints rather than mo-
lecular measures of drug effects are used for the selection of the
recommended phase II dose [30]. This is probably due, in most cases,
to the difficulty of obtaining the tumor biopsies that are required to
perform standard assays of drug action on molecular targets. The devel-
opment of surgically noninvasive endpoints is, therefore, particularly
important because they would avoid the need for tumor biopsy [27].
In vivo phosphorus magnetic resonance spectroscopy (31P MRS) is a
noninvasive technique that provides biochemical information about
both healthy and diseased tissues in many parts of the body [31]. This
technique has also been used to study the biochemistry and physi-
ology of tumor cells and solid cancers, and it has shown potential in
the assessment of response after therapies in both human and animal
models [32–39]. Markers for tissue bioenergetics, such as nucleoside
triphosphates (NTPs), inorganic phosphate (Pi), and intracellular pH
(pHi), as well as various phosphorus-containing components of phos-
pholipid metabolism, are readily observed using 31P MRS. In tumors,
the phosphomonoesters (PMEs) are mainly phosphocholine (PC)
and phosphoethanolamine (PE), precursors of the membrane phos-
pholipids phosphatidylcholine and phosphatidylethanolamine, respec-
tively, whereas the phosphodiesters (PDEs) are glycerophosphocholine
(GPC) and glycerophosphoethanolamine (GPE), which are break-
down products of phosphatidylcholine and phosphatidylethanolamine,
respectively. Therefore, changes in phospholipids could provide useful
information about tumor cell membrane metabolism. However, in
several published studies, the changes in the phospholipid have been
attributed to the modulation of various signaling pathways and were
mostly independent of membrane metabolism [38,39].
To predict the efficacy of LAQ824 by 31P MRS in vivo in clini-
cal trial patients, we investigated the pharmacodynamic effects of
LAQ824 in a human colon carcinoma model in mice, using both
in vitro and in vivo MRS techniques, because MR spectra of biopsy
extracts yields better peak resolution; 1H MRS was used on tumor
extracts ex vivo to characterize changes in nonphosphorylated metabo-
lites. We also examined 31P MR spectra of extracts of a human colon
carcinoma cell line, HT29, using two different HDAC inhibitors: sub-
eroylanilide hydroxamic acid (SAHA; Vorinostat) [40] and the novel
HDAC inhibitor, LAQ824 [24]. Suberoylanilide hydroxamic acid was
included in these experiments as a second HDAC inhibitor with a dif-
ferent chemical structure to verify that some of the effects seen with
LAQ824 were associated with HDAC inhibition. We also conducted
an in vivo MRS study on the effects of LAQ824 on the HT29 xeno-
graft model: (1) to demonstrate therapeutic efficacy; (2) to determine
whether MRS changes observed in the cell studies were reproducible
in vivo; and (3) to investigate whether 31P MRS could provide a non-
invasive pharmacodynamic biomarker for the therapeutic action of
HDAC inhibitors that could be used in future clinical trials. In addi-
tion, the effects of LAQ824 on tumor microvessel density and histone
H3 acetylation status were determined to see if vascular and molecular
effects accompanied changes in the MR spectrum. As HDAC inhibi-
tion impacts on Hsp90 activity [19–24], we also probed for the mo-
lecular signature of Hsp90 inhibition by determining levels of the
client protein C-RAF and the molecular cochaperone heat shock pro-
tein 70 (Hsp70).
Materials and Methods
Materials
LAQ824 was provided by Novartis (Hanover, NJ) and SAHA was
purchased from Alexis Corporation (Nottingham, UK). Both drugs
were dissolved in dimethylsulfoxide (DMSO) and stock solutions
were stored at −20°C. Dulbecco’s modified Eagle’s medium, fetal
calf serum (FCS), penicillin, and streptomycin were purchased from
Gibco (Paisley, UK); EDTA, perchloric acid (PCA), and potassium
hydroxide were from Merck (Poole, UK); Hypnorm was obtained
from Jansen Pharmaceuticals (Buckinghamshire, UK); Hypnovel
was from Roche (Welwyn Garden City, UK); and all other chemicals
were purchased from Sigma (Poole, UK).
Cell Culture
HT29 human colon carcinoma cells were grown in Dulbecco’s
modified Eagle’s medium containing 10% heat-inactivated FCS with
100 U/ml penicillin and 100 μg/ml streptomycin. Cells were main-
tained at 37°C in a humidified 5% CO2 atmosphere, and growth
media were replenished every 48 hours.
Growth Inhibition Assay
The effect of drug treatment on cell proliferation was measured
using the sulforhodamine B (SRB) assay [41]. For this, cells growing
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in 96-well microtiter plates were treated with varying concentrations of
LAQ824 or SAHA for 96 hours. At the end of incubation, plates were
fixed in 150 μl of cold trichloroacetic acid for 30 minutes then stained
overnight with 0.4% (w/v) SRB made up in 1% acetic acid. Plates
were washed in 1% acetic acid to remove excess dye, treated with
150 μl of 10 mM Tris to dissolve protein-bound SRB and then read
on a plate reader at 570 nm (Molecular Devices, Sunnyvale, CA).
HDAC Inhibition for In Vitro MR Measurements
HT29 cells were treated with 34 μM SAHA [i.e., 20× of the 50%
growth inhibition concentration (GI50)] and 350 nM LAQ824 (i.e.,
10× GI50) for 24 hours to achieve a ca. 50% decrease in cell number
per flask and an inhibition of HDAC as measured by Western blot
analysis (see below) at the time of cell extraction. Higher concen-
trations of SAHA and LAQ824 were used to treat HT29 cells be-
cause the GI50 values quoted previously were based on 96 hours’
drug exposure rather than the 24 hours’ exposure used in these
experiments. The effect of HDAC inhibition on cell counts was as-
sessed by determining the number of attached cells using the trypan
blue exclusion method.
HT29 Tumor Xenograft Model
Eight-week-old MF-1 male nude mice, weighing 30 to 38 g, were
injected subcutaneously in the flank with 0.2 ml of HT29 (2.5 ×
107 cells/ml) human colon carcinoma cells that had been grown as
a monolayer in culture [36]. Tumor volume was calculated by mea-
suring the length, width, and depth of each tumor using calipers and
by using the following formula: l × w × d × (π/6). Once an appro-
priate tumor size (approximate volume of 500 mm3) was established,
mice were randomly divided into two groups; one group was treated
with LAQ824 in the delivery vehicle (10% of DMSO and 90% of
5% dextrose in water) at 25 mg/kg intraperitoneally (i.p.) once a
day for 2 days (n = 20; initial tumor volume, 537 ± 31 mm3) and
one group was treated with the delivery vehicle alone (n = 18; initial
tumor volume, 484 ± 36 mm3). A cohort of animals (7 vehicle- and
11 LAQ824-treated) was used in the MRS study, and tumors were
excised on day 4 for Western blot, histologic, vascular, or in vitro
MRS analysis. Tumors from another cohort of animals (6 vehicle-
and 4 LAQ824-treated) were excised on day 4 and were used for his-
tologic or Western blot analysis. A third cohort of animals (5 vehicle-
and 5 LAQ824-treated) was used in the tumor growth delay study
where the animals were treated for 2 days (same dosing schedule as
the MRS study), and the tumor volumes were monitored for a fur-
ther 8 days after the last dose. Animals were treated in accordance
with the local and national ethical requirements and with the United
Kingdom Co-ordinating Committee on Cancer Research Guidelines
for the Welfare of Animals in Experimental Neoplasia [42].
Despite that the mouse tumors have a higher tumor-to-host weight
ratio than human tumors, the previously reported noninvasive MRS
biomarkers have been useful in translating into clinic [32–34].
In Vitro 31P MRS of Cell Extracts
Control and treated cells were extracted in equal volumes of cold
methanol, chloroform and water, and lyophilized samples of the
water-soluble fraction were reconstituted in 700 μl of deuterated
water (D2O) containing 10 mM EDTA and 2 mM methylenediphos-
phonic acid (an internal reference) at pH 8.2 [43]. 31P MR spectra
were recorded on a 500-MHz spectrometer (Bruker, Coventry, UK)
using power-gated composite-pulse 1H decoupling, a 30° flip angle,
a 2-second repetition time and a spectral width of 100 ppm. Data were
processed using a line broadening of 1 Hz and were analysed using
MestRe-C version 2.3 (University of Santiago de Compostela, Spain).
The metabolite content was determined by peak integration, normal-
ized relative to the internal standard, and corrected for saturation and
cell number in each sample.
In Vivo 31P MRS of HT29 Tumor Xenografts
Animals were anesthetized with a single i.p. injection of a Hypnovel-
Hypnorm-water (1:1:2) mixture as previously described [36]. Ani-
mals were placed in the bore of a 4.7-T nuclear magnetic resonance
(NMR) spectrometer (Varian, Palo Alto, CA) at St. George’s University
of London, and tumors were positioned in the center of a 12-mm two-
turn 1H/31P surface coil. Image-selected in vivo spectroscopy–localized
31P MR spectra of the tumors were obtained at 37°C as previously
described [44]. Briefly, a gradient strength of up to 7.5 × 10−4 T/cm
was applied with adiabatic pulses of 800 milliseconds, a sin/cos
90° excitation pulse, and a sech 180° inversion pulse, with a total
repetition time of 3 seconds and 600 averages. In vivo 31P MRS of
the tumors was carried out before treatment (i.e., day 1) and the day
after the last dose (i.e., day 4). Proton decoupling was not used in
these experiments because it was not available in our MR system.
31P MR spectra were quantified using the Variable Projection pro-
gram (VARPRO) to determine precise chemical shifts and peak inte-
grals as previously described [45]. After the final 31P MRS study, the
tumors were excised, and part of the tumor was snap-frozen for im-
munohistochemical staining of CD31 and part was freeze-clamped
and stored at −80°C for subsequent immunoblot analysis or extrac-
tion for in vitro 1H and 31P MRS analyses. The excised tumors were
weighed after freezing to minimize tissue degradation.
The surface coils used to obtain the 31P MRS signal from subcuta-
neous tumors in vivo are of a nonuniform spatial sensitivity, making
it impossible to use an external standard. As a result, the signal in-
tensities observed in the in vivo 31P MR spectra are expressed as ratios
of metabolites.
In Vitro 1H and 31P MRS of Tumor Extracts
About 200 mg of the freeze-clamped HT29 tumors were extracted in
6% ice-cold PCA, and the extraction procedures were performed on ice
as previously described [46]. Neutralized extracts were freeze-dried and
reconstituted in 1 ml of D2O, and the extracts (0.5 ml) were placed in
5-mm NMR tubes. For the 1H MRS, the water resonance was sup-
pressed by using gated irradiation centered on the water frequency. So-
dium 3-trimethylsilyl-2,2,3,3-tetradeuteropropionate (50 μl, 5 mM)
was added to the samples for chemical shift calibration and quantifica-
tion. Immediately before the MRS analysis, the pH of the samples was
readjusted to 7 with PCA or potassium hydroxide. For the 31P MRS,
which was carried out after the 1H MRS study, EDTA (50 μl, 60 mM)
was added to each sample to chelate metals ions, and MDPA (50 μl,
5 mM) was added to each sample for chemical shift calibration and
quantification. The extract spectra for both the control and the treated
animals were acquired under identical conditions.
In vitroMRSwas performed on tumor extracts to confirm our in vivo
MR findings. Water-soluble metabolites were measured in vitro to pro-
vide the most appropriate match to our in vivo results. The PCA extrac-
tion method was used, because this is the method that is routinely
carried out on tumor samples in our laboratory. However, we have used
a dual-phase extraction method (methanol and chloroform) on cell
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extracts in vitro and detected similar changes in the water-soluble frac-
tions as those detected in the PCA-extracted tumors.
Western Blot Analysis
The molecular effects of HDAC inhibition on HT29 cells and
xenografts were assessed by Western blot analysis for levels of acetyl
histone H3, C-RAF, and Hsp70 protein expression. Cell pellets were
resuspended in lysis buffer A (150 mM NaCl, 28.2 mM Tris-HCl,
1.1 mM Tris base, 0.2% sodium dodecyl sulfate, 1% Nonidet P-40,
10% glycerol, 0.5 mM sodium orthovanadate, 10 mM sodium pyro-
phosphate, 0.1 M NaF, and 1 mM EDTA) and 50 to 100 mg of
ground tumor tissues were resuspended in lysis buffer B (150 mM
NaCl, 50 mM Tris, pH 7.4, 1 mM EDTA, 1% Triton X-100, 1 mM
NaF, 1 mM sodium orthovanadate, 1% protease cocktail, 1 mM di-
thiothreitol, 0.1% fenvalerate, and 1 mM phenylmethylsulfonyl fluo-
ride). Equal amounts of protein, measured using either the Bio-Rad
assay method (for cell pellets, n = 3 for each treatment group) (Bio-
Rad, Hemel Hempstead, UK) or the bicinchonic acid reagent assay
method (for tumor tissues, n = 5 for the control group and n = 8 for
the LAQ824-treated group) (Pierce, Northumberland, UK) and bovine
serum albumin as a standard, were loaded onto 12% (for cell pellets) or
4% to 12% (for tumor tissues) polyacrylamide gels. Cell lysate protein
was transferred onto Immobilon-P membranes (Millipore, Bedford,
MA), and tumor lysate protein was transferred onto polyvinylidene
fluoride membranes. Blots were blocked in 5% nonfat milk for 2 hours
and then incubated with primary anti–acetyl histone H3 antibody
(Upstate, Charlottesville, VA), anti–C-RAF antibody (Santa Cruz Bio-
technology, Santa Cruz, CA) or anti-Hsp70 (Stressgen Bioreagents,
Ann Arbor, MI). This was followed by incubating the membranes
with horseradish peroxidase–conjugated anti–rabbit secondary anti-
body for C-RAF and acetyl histone H3, and anti–mouse secondary
antibody for Hsp70 (Amersham Biosciences, Buckinghamshire, UK).
Equal gel loading was verified by incubating the blots with an anti–
glyceraldehyde-3-phosphate dehydrogenase antibody (Chemicon,
Hampshire, UK) or with β-actin (Abcam, Cambridge, UK) fol-
lowed by an anti–mouse secondary antibody in 5% nonfat milk for
1 hour. Specific binding antibody–target protein interactions were de-
tected using enhanced chemiluminescence plus reagents (Amersham
Biosciences) and exposure to either Hyperfilm ECL (Amersham Bio-
sciences) or X-OMAT Kodak (Rochester, NY) autoradiography film.
Immunohistochemistry
The microvessel density of HT29 tumors after vehicle and LAQ824
treatment was assessed by immunohistochemical staining for the
vascular endothelial adhesion molecule, CD31. Snap-frozen tumor
samples were sectioned and fixed in acetone. Sections were blocked
in endogenous peroxidase (600 μl of 30% hydrogen peroxide in
100 ml of phosphate buffer solution) for 5 minutes and then incubated
with primary CD31 antibody (01951D; PharMingen, Cambridge,
UK) (diluted 1:50) for 35 minutes. The sections were further incu-
bated in biotinylated rabbit anti–rat biotin (BA 5001; Vector Labora-
tories, Peterborough, UK) (diluted 1:100) for 35 minutes and followed
by streptavidin horseradish peroxidase (P0397; Dako, Stockport, UK)
(diluted 1:500) for a further 35 minutes. The sections were then finally
developed in DAB, and nuclear counterstaining was performed with
Harris’ hematoxylin (Dako).
The method described by Qian et al. [25] was used for the micro-
vessel density measurements. Briefly, analySIS (Soft Imaging System
GmbH, Münster, Germany) was used to quantify the area occupied
by the vessels in the histologic sections. The mean area per field from
10 fields per section (×200 = ×20 objective lens and ×10 ocular lens)
was calculated and expressed as the mean percentage area occupied
by blood vessels per field ± SEM. The experiment was repeated.
Histology
Part of the excised tumor was fixed in formal saline. Paraffin-
embedded sections were cut and stained with Ehlich’s hematoxylin
and eosin (Dako) for the assessment of necrosis.
Cell Cycle Analysis
The effect of HDAC inhibition with LAQ824 and SAHA on cell
cycle distribution was assessed in HT29 cells using flow cytometry
and propidium iodide staining, as previously described [38].
Statistical Analysis
Data are presented as the mean ± SEM. For comparison of me-
tabolite concentrations, metabolite ratios, and microvessel density,
Student’s standard t tests were used, with P ≤ .05 considered to be
statistically significant. Pearson correlation was used to correlate
changes in tumor volume and PME/total phosphorus (TotP) signal
ratios, with P ≤ 0.05 considered to be statistically significant. All sta-
tistical tests were two-sided.
Results
Effect of HDAC Inhibition By SAHA and LAQ824
in HT29 Cells
Treatment of HT29 human colon carcinoma cells with SAHA
and LAQ824 in vitro resulted in a significant antiproliferative effect
with GI50 values for 96 hours’ exposure of 1.7 ± 0.1 μM (n = 3) and
34.9 ± 1.3 nM (n = 3), respectively, as determined by the SRB assay.
Exposure of HT29 cells in vitro to 34 μM SAHA and 350 nM
LAQ824 for 24 hours in our MRS experiments led to a substantial
reduction in cell count to 47 ± 5% (P = .001) and 50 ± 3% (P =
.0001) of controls, respectively. Western blot analysis showed that
acetyl histone H3 levels were markedly increased after exposure to
both drugs consistent with HDAC inhibition (Figure 1 A). C-RAF
decreased substantially, whereas Hsp70 levels remained unchanged
after treatment (Figure 1 A). Flow cytometry indicated that HDAC
inhibition with SAHA and LAQ824 was associated with significant
alterations in cell cycle profiles. Exposure to SAHA and LAQ824 in-
duced an accumulation in the G1 phase from 25 ± 1% to 35 ± 1%
(n = 3, P = .009) and 49 ± 3%, respectively (n = 3, P = .007). Fur-
thermore, a reduction in the S-phase population (from 60 ± 2% to
20 ± 1%, P = .0001 and 21 ± 3%, P = .0026) and an increase in the
G2/M–phase populations (from 15 ± 1% to 45 ± 1%, P = .0002 and
30 ± 1%, P = .0002) were recorded after treatment with SAHA and
LAQ824, respectively. Figure 2 A illustrates an example of 31P MR
spectra acquired from the aqueous fractions of extracts originating
from control, SAHA-, and LAQ824-treated HT29 cells. 31P MRS
analysis indicated that inhibition of HDAC with LAQ824 and
SAHA was associated with a significant increase of up to twofold
in the levels of cellular PC (Table 1). Interestingly, no other signifi-
cant alterations were observed in the spectra of cells exposed to either
SAHA or LAQ824 (see Table 1).
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Effect of LAQ824 on HT29 Xenografts In Vivo
Significant tumor growth inhibition was observed in HT29 xeno-
grafts after 2 days of LAQ824 treatment (25 mg/kg) when compared
with vehicle-treated controls (Figure 1 B). The percentage inhibition
was 72% at day 4, during which time the tumor volumes increased
by 43 ± 5% in the vehicle-treated group and by 12 ± 3% in the
LAQ824-treated group (P = .0003). The percentage inhibition was
46% at day 11, during which time the tumor volumes increased
from day 1 by 209 ± 29% in the vehicle- and by 112 ± 18% in
the LAQ824-treated group (P < .0001). This study also showed that
significant tumor growth delay persisted for many days after the last
dose of LAQ824 (Figure 1 B).
In vivo 31P MR spectra from a HT29 tumor pre– and post–
LAQ824 treatment are shown in Figure 2 B, where resonances from
PME, PDE, Pi, α-, β-, γ-NTP, and phosphocreatine (PCr) can be
observed. Marked decreases in NTP and PCr and an increase in Pi
levels were found in LAQ824-treated tumors (Figure 2 B). This ob-
servation indicates that tumor bioenergetics is severely compromised
after treatment. Statistically significant increases in PME/TotP (P =
.003) and Pi/TotP ratios (P = .0002) and decreases in β-NTP/TotP
(P = .001), β-NTP/Pi (P = .003), and PCr/TotP (P = .004) ratios and
pHi (P = .02) were observed post–LAQ824 treatment (Table 2). No
statistically significant change in the metabolite ratio was observed in
the control (vehicle-treated) tumor group (Table 2).
Western blots of the excised tumors showed increased histone H3
acetylation in the LAQ824-treated group (Figure 1 A). These results
confirm the expected inhibitory effect of LAQ824 on HDAC in
HT29 xenografts. C-RAF expression decreased after LAQ824 treat-
ment, but the expression of Hsp70 remained unchanged after treat-
ment (Figure 1 A).
Relationship Between PME/TotP Ratios and
Tumor Response
We examined the degree of association between PME/TotP ratio
and tumor response. This was done by comparing the individual %
change in PME/TotP (posttreatment ratio relative to pretreatment
ratio) ratios from the cohorts of vehicle- and LAQ824-treated tumors
with their corresponding % change in tumor volumes (posttreatment
volume relative to pretreatment volume). A statistically significant in-
verse correlation was found between percentage increase in PME/
TotP ratio and percentage change in tumor volume (r = −0.61, P =
.01) (Figure 3).
Effect of LAQ824 on HT29 Tumor Extracts
In vitro 31P MRS analysis of extracts of the HT29 tumor xeno-
grafts allows better resolution of the metabolite signals than is possi-
ble in vivo. Increased levels of PC (P = .04), PE (P = .02), and Pi (P =
.06) and decreased levels of GPC (P = .01) and GPE (P = .05) were
detected in LAQ824-treated tumors (Table 3 A) relative to controls,
confirming our in vivo 31P MRS findings.
In vitro 1H MR spectra (expanded from 0.5 to 5.5 ppm) of the
HT29 tumor extracts from a control vehicle-treated and a LAQ824-
treated mouse are illustrated in Figure 2 C, respectively, showing
resonances from leucine, iso-leucine, valine, lactate, alanine, acetate,
glutamine, glutamate, creatine, PCr, free choline, PC, GPC, taurine,
glycine, and glucose [47]. Elevated PC (P = .04), free choline (P =
.01), leucine (P = .005), iso-leucine (P = .005), and valine (P = .04)
levels and reduced GPC (P = .02), glutamate (P = .04), glutamine (P =
.03), glucose (P = .001), and PCr and creatine (P = .05) levels were
found in LAQ824-treated HT29 tumor extracts when compared with
vehicle-treated tumor extracts (Table 3 B).
Histologic and Vascular Effect of LAQ824
on HT29 Xenografts
Histologic sections of a control and a LAQ824-treated HT29
tumor are shown in Figure 1 C. LAQ824-treated tumors showed ex-
tensive necrosis when compared with vehicle controls.
Microvessel density in vehicle- and LAQ824-treated HT29 tumors
was assessed by immunohistochemical staining for CD31. A marked
reduction of CD31 staining and a significant decrease by 67% in
microvessel density was found in LAQ824-treated tumors (25 mg/kg
for 2 days) when compared with controls (P = .007; Figure 1, C andD).
Discussion
Pharmacodynamic and tumor response biomarkers are increasingly
important for the development of new molecular therapeutics [27–
29]. Histone deacetylase inhibition causes increased or decreased ex-
pression of a variety of genes that mediate proliferation, cell cycle
progression, angiogenesis, and apoptosis [7–19] and perturb the acet-
ylation status of many proteins in addition to histones [19–24]. Tu-
mor response to LAQ824 can be assessed using molecular biologic
markers, particularly the induction of histone H3 and H4 hyperacet-
ylation [22–26] and the depletion of Hsp90 client proteins, such as
C-RAF. However, a noninvasive, direct, or surrogate marker of tumor
response to this novel treatment would be of value [27].
In our study, inhibition of HDAC in HT29 cells by LAQ824 or
SAHA was demonstrated by the induction of histone H3 acetylation
usingWestern blot analysis. The reduction in expression of the Hsp90
client protein, C-RAF, is consistent with Hsp90 inhibition after expo-
sure to HDAC inhibitors [19,21–24,48,49]. However, the induction
of Hsp70 expression, which is also a marker of Hsp90 inhibition [49],
was not observed in our cell and tumor samples. This observation has
also been reported previously in prostate cancer cells after HDAC in-
hibition with a SAHA analog [48], and the explanation for this find-
ing remains unknown. This may result from a direct inhibitory effect
of HDAC inhibition on Hsp70 induction.
The molecular signature of HDAC inhibition as defined by the
above changes in the HT29 cell line, and in previous studies [13,24–
26,40], was also seen in the HT29 xenografts. Growth inhibition was
observed in both HT29 cells and tumors. Flow cytometry of HT29
cells treated with SAHA or LAQ824 showed significant alterations in
cell cycle distributions when compared with controls. Both drugs in-
duced a G1- and a G2/M–phase accumulation as well as a reduction
in the S-phase population. This observation indicates cell cycle arrest
after HDAC inhibition and is consistent with the reported effect of
HDAC inhibition on cell cycle progression [10,11,24,26,48].
The primary aim of this project was to develop a noninvasive
31P MRS marker of response to the HDAC inhibitor LAQ824. To
facilitate this, we looked for metabolite changes indicative of tumor re-
sponse both in vitro (HT29 cells) and in vivo (HT29 xenografts). Con-
centrations used on HT29 cells in vitro were those that caused around
50% cell growth inhibition over 24 hours and an increase in histone
acetylation. The dose used to treat HT29 tumors in vivo was well
tolerated (as no significant weight loss was found after treatment)
and caused tumor growth inhibition, again with evidence of target
modulation shown by an increase in histone acetylation. HT29 cells
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treated with HDAC inhibitors (LAQ824 and SAHA) showed a statis-
tically significant increase in PC levels. In the HT29 xenograft model,
we also observed a significant MRS-detectable increase in the PME
peak (with contributions from both PC and PE) post–LAQ824 treat-
ment. A significant correlation was also found between the increased
PME/TotP ratio and tumor response. The principal sources of PME
signals in tumors are PC and PE, precursors of phosphatidylcholine
and phosphatidylethanolamine, which are major components of bio-
logic membranes [50]. This increase in PME is confirmed by the sig-
nificant rises in PC and PE levels observed in 1H and 31P MR spectra
of LAQ824-treated tumor extracts when compared with controls.
These results are consistent with findings from a recent study in a human
prostate cancer (PC3) cell line, which also showed (using in vitro
MRS of cell extracts) that PC levels increase after HDAC inhibition
with a SAHA analog [48], indicating that these observations are not
cell line–specific or tissue type–dependent.
Figure 1. LAQ824 causes induction of histone acetylation and reduction of C-RAF expression, tumor growth delay, extensive tumor
necrosis, and reduction of microvessel density in HT29 tumor model. (A) Western blots for Hsp70 and C-RAF expression and histone
(H3) acetylation are shown in HT29 cells after treatment with vehicle (left lane), 34 μM SAHA [20 × GI50] (middle lane), and 350 nM
LAQ824 [10 × GI50] (right lane) for 24 hours (left panel). Western blots for histone (H3) acetylation and C-RAF and Hsp70 expression
are shown in HT29 xenografts following daily (×2) i.p. injection of vehicle (10% DMSO and 90% of 5% dextrose in water) (lanes 1–5) and
25 mg/kg LAQ824 i.p. (lanes 6–10) (right panel). (B) Percentage change in tumor volumes (tumor volume post–LAQ824 or –vehicle treat-
ment relative to pretreatment volume) over time are shown in HT29 xenografts following daily (×2) i.p. injection of vehicle (10% DMSO
and 90% of 5% dextrose in water) and 25 mg/kg LAQ824 i.p. Vehicle-treated (filled squares; n = 18 at days 1, 3, and 4 and n = 5 at days
8, 10, and 11) and LAQ824-treated group (filled diamonds; n = 20 at days 1, 3, and 4 and n = 5 at days 8, 10, and 11) are shown in the
graph. Treatment days are shown by black arrows. Results are expressed as mean ± SEM. Two-tailed unpaired t test was used to
compare changes between the vehicle- and LAQ824-treated groups. *P ≤ .03 and ^P = .08 when comparing LAQ824-treated with
vehicle controls. (C) Hematoxylin and eosin (H&E) staining for necrosis (top panels; original magnification, ×40) and immunohistochem-
ical staining of CD31 for endothelial cells are shown (blood vessels are in brown) (bottom panels; original magnification, ×200) in HT29
xenografts after daily (×2) i.p. injection of vehicle (10% DMSO and 90% of 5% dextrose in water) (left panels) and 25 mg/kg LAQ824 i.p.
(right panels). Some areas of necrosis are shown by the black arrows. (D) Quantitative analysis of microvessel density was performed in
LAQ824- and vehicle-treated tumors using analySIS (Soft Imaging System GmbH). Results are expressed as percent microvessel area
per field, mean ± SEM. Two-tailed unpaired t test was used to compare changes between the vehicle- (n = 2) and LAQ824-treated
groups (n = 3). *P = .007 when comparing LAQ824-treated with vehicle controls.
Figure 2. Inhibitions of HDAC by LAQ824 are associated with a significant drop in tumor bioenergetics and increase in phosphomono-
esters and phosphocholine levels. (A) In vitro 31P MRS of an HT29 cell extract treated with: vehicle (bottom panel), 34 μM SAHA (middle
panel), and 350 nM LAQ824 (top panel) for 24 hours. Peak assignments: phosphocholine (PC), glycerophosphocholine (GPC), glycero-
phosphoethanolamine (GPE), inorganic phosphate (Pi), phosphocreatine (PCr), and nucleoside triphosphates (α-, β-, γ-NTP). (B) In vivo
31P MR spectra of a HT29 tumor before (top panel) and after (bottom panel) LAQ824 treatment (25 mg/kg i.p. for 2 days) are shown. Peak
assignments: phosphomonoesters (PME), phosphodiesters (PDE), inorganic phosphate (Pi), phosphocreatine (PCr), and nucleoside tri-
phosphates (α-, β-, γ-NTP). (C) In vitro 1H MR spectra of vehicle- (top panel) and LAQ824-treated (bottom panel) HT29 tumor extracts are
illustrated. Peak assignments: leucine (1), iso-leucine (2), valine (3), lactate (4), alanine (5), acetate (6), glutamate (7), glutamine (8), di-
methylamine (9), creatine + phosphocreatine (10), free choline (11), phosphocholine (12), glycerophosphocholine (13), taurine (14), gly-
cine (15), creatine (16), phosphocreatine (17), water (18), glucose (19).
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Although both PC and PE peaks were observed in untreated tu-
mor extracts, only the PC peak was observed in the cultured cell ex-
tracts. Similar findings [51] in HT29 tumor xenografts and cultured
cells have been attributed to the greater availability of ethanolamine
in vivo when compared with cells in culture, where ethanolamine is
only present in added serum. The relative amounts of PC and PE,
both of which contribute to the PME signal, appear to vary among
both experimental models and human tumors in patients [52].
It is possible that other agents with HDAC inhibitory properties
could produce different results, e.g., Milkevitch et al. [53] reported a
Figure 2. (continued)
310 MRS Markers for Histone Deacetylase Inhibition Chung et al. Neoplasia Vol. 10, No. 4, 2008
rise in GPC in prostate cancer cells in vitro after treatment with phe-
nylbutyrate. This may have been because this agent is less selective
than SAHA and LAQ824 as an inhibitor of HDACs or to differences
in the in vitro culture conditions.
In vitro increases in PC have been observed in two different cancer
lines (HT29 and PC3 [48]) with two different HDAC inhibitors
(SAHA and LAQ824), and in vivo increases in PME (after
LAQ824 treatment) have also been found. It would be possible to
measure these PME and PC changes (as total choline) in vivo by
1H MRS as a potential biomarker. For ease of measurement, the
1H MRS measurements were limited to tumor extracts in this study.
As mentioned, the depletion of C-RAF after HDAC inhibition is
consistent with Hsp90 inhibition after exposure to HDAC inhibi-
tors. Thus, it is of interest that HDAC inhibition also results in in-
creased PC and PME levels, because similar molecular and spectral
changes were found in HT29 cells and in xenografts after treatment
with the Hsp90 inhibitor 17-allylamino,17-demethoxygeldanamycin
[36]. The basis for the increased levels of PC and PME warrants fur-
ther investigation, but it appears that Hsp90 modulation may be im-
plicated. Phospholipid changes have previously been attributed to the
modulation of various signaling pathways [38,39].
Marked and significant decreases in high-energy phosphates (β-
NTP/TotP, β-NTP/Pi, and PCr/TotP ratios) and pHi and an increase
in a low-energy phosphate (Pi/TotP ratio) were observed in HT29
tumors post–LAQ824 treatment. These changes suggest that tumor
bioenergetics is severely compromised after treatment. This dramatic
drop in tumor bioenergetics after treatment of LAQ824 has not been
reported previously. These in vivo bioenergetic changes and in vitro
metabolic changes (as detected by in vitro 1H and 31P MRS of tumor
extracts) are consistent with a reduced perfusion in HT29 tumors
after treatment with LAQ824. Indeed, similar dramatic effects on tu-
mor bioenergetics were reported in HT29 tumors after treatment
Table 1. The Effect of Treatment with SAHA and LAQ824 on the 31P MRS Detectable Aqueous
Metabolites of HT29 Human Colon Carcinoma Cells (N = 4).
Metabolites Control LAQ824 SAHA
PC 19 ± 1 38 ± 5* 42 ± 4†
GPC 7 ± 1 6 ± 1 7 ± 1
GPE 3 ± 1 5 ± 1 5 ± 1
NTP 9 ± 1 13 ± 3 12 ± 2
Metabolite content is expressed as femtomole per cell. Data are expressed as mean ± SEM.
Two-tailed unpaired t test was used to compare changes between the vehicle-, SAHA-, and
LAQ824-treated groups: *P = .04 and †P = .01.
PC indicates phosphocholine; GPE, glycerophosphoethanolamine; GPC, glycerophosphocholine;
NTP, nucleoside triphosphate.
Table 2. In Vivo 31P Magnetic Resonance Spectroscopy of HT29 Tumors.
(A) Pre– and Post–Vehicle Treatment (N = 7)
Metabolite Ratios Pre-Vehicle Post-Vehicle P†
PME/TotP 0.18 ± 0.01 0.18 ± 0.02 NS
β-NTP/TotP 0.21 ± 0.01 0.21 ± 0.01 NS
PCr/TotP 0.10 ± 0.01 0.09 ± 0.02 NS
β-NTP/Pi 3.15 ± 0.55 2.50 ± 0.35 NS
Pi/TotP 0.06 ± 0.03 0.09 ± 0.01 NS
pHi 7.12 ± 0.06 7.14 ± 0.06 NS
(B) Pre– and Post–LAQ824 Treatment (N = 11)
Metabolite ratios Pre-LAQ824 Post-LAQ824 P
PME/TotP 0.18 ± 0.01 0.23 ± 0.01 .003
β-NTP/TotP 0.21 ± 0.01 0.13 ± 0.02 .001
PCr/TotP 0.08 ± 0.01 0.04 ± 0.01 .004
β-NTP/Pi 2.62 ± 0.33 1.09 ± 0.43 .003
Pi/TotP 0.09 ± 0.01 0.21 ± 0.03 .0002
pHi 7.08 ± 0.03 6.93 ± 0.04 .02
Data are expressed as mean ± SEM.
PME indicates phosphomonoester; TotP, total phosphorus signal; β-NTP, β-nucleoside triphos-
phate; Pi, inorganic phosphate; pHi, intracellular pH; PCr, phosphocreatine; NS, not statistically
significant (P > .1).
†Two-tailed paired t test was used to compare changes pre– and post–LAQ824 treatment within
the same group of animals.
Table 3. In Vitro Magnetic Resonance Spectroscopy of HT29 Tumor Extracts Following Vehicle
and LAQ824 Treatment.
Metabolites (μmol/g wet weight) Control (N = 5) LAQ824 (N = 5) P†
(A) Phosphorus MRS
PE 1.13 ± 0.20 1.85 ± 0.09 .02
PC 1.87 ± 0.21 2.72 ± 0.21 .04
GPE 1.66 ± 0.44 0.49 ± 0.10 .05
GPC 2.34 ± 0.33 0.81 ± 0.08 .01
Pi 5.01 ± 0.91 9.00 ± 1.23 .06
(B) Proton MRS
PC 1.76 ± 0.16 2.51 ± 0.25 .04
GPC 2.05 ± 0.23 1.26 ± 0.13 .02
Free choline 0.16 ± 0.03 0.49 ± 0.08 .01
Leucine 0.23 ± 0.03 0.41 ± 0.08 .005
Iso-leucine 0.11 ± 0.02 0.22 ± 0.02 .005
Valine 0.26 ± 0.04 0.39 ± 0.04 .04
Glutamate 2.05 ± 0.35 0.97 ± 0.09 .04
Glutamine 0.88 ± 0.11 0.44 ± 0.12 .03
PCr + Cr 5.19 ± 0.70 2.40 ± 0.99 .05
Glucose 0.95 ± 0.06 0.37 ± 0.08 .001
Lactate 6.84 ± 0.79 5.80 ± 2.24 NS
Alanine 1.82 ± 0.26 2.05 ± 0.10 NS
Taurine 6.91 ± 0.82 5.17 ± 0.42 NS
Glycine 1.46 ± 0.18 1.23 ± 0.05 NS
Data are expressed as mean ± SEM.
PE indicates phosphoethanolamine; PC, phosphocholine; GPE, glycerophosphoethanolamine;
GPC, glycerophosphocholine; PCr, phosphocreatine; Cr, creatine; Pi, inorganic phosphate; NS,
not statistically significant (P > .1).
†Two-tailed unpaired t test was used to compare changes between the vehicle- and LAQ824-treated
groups.
Figure 3. The increased PME/TotP ratio was correlated with tumor
response. The percentage change in PME/TotP ratios (posttreat-
ment values relative to pretreatment values) is plotted against per-
centage change in tumor volumes (posttreatment values relative
to pretreatment values). Solid line indicates linear regression line:
r = −0.61, P = .01.
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with the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic
acid [54].
Surprisingly, no significant change in lactate was found in LAQ824-
treated tumor extracts when compared with vehicle-treated controls, as
one may expect an increase in tumor lactate when tumor perfusion is
reduced. This observation has also been previously reported in xeno-
grafts treated with a vascular disrupting agent, ZD6126 [55], and the
explanation for this finding remains unclear.
To confirm whether LAQ824 exerts a vascular effect in HT29
tumor xenografts, immunohistochemical staining of the vascular endo-
thelial adhesion molecule, CD31, was carried out on frozen sections
of vehicle- and LAQ824-treated tumors. A significant reduction in
microvessel density was found in LAQ824-treated tumors when com-
pared with vehicle controls; this finding, together with extensive necro-
sis and a dramatic drop in tumor bioenergetics, is consistent with the
hypothesis that LAQ824 reduces perfusion in HT29 tumors. A reduc-
tion in microvessel density was also previously reported in LAQ824-
treated PC3 and MDA-MB231 tumors, where LAQ824 treatment
was found to inhibit the expression of angiogenesis-related genes,
such as angiopoietin-2, Tie-2, and survivin in endothelial cells, and
downregulation of HIF-1α and VEGF expression in tumor cells
[25]. Weinberg [56] has recently suggested that the effectiveness of con-
ventional chemotherapeutics may be strongly influenced by the sensi-
tivity of the tumor-associated microvasculature to these agents. This
dual action of LAQ824 appears to be an example of such an effect.
The reduction in perfusion observed in LAQ824-treated tumors is
likely to cause tumors to become deprived of essential nutrients. This
may explain the dramatic drop in in vivo tumor bioenergetics and
significant decrease in glucose, PCr + Cr, glutamine, and glutamate
levels (these metabolites may be used by the tumor to produce energy
when the nutrient supply is low) observed through in vitro 1H MRS
of tumor extracts.
In vitro 1H and 31P MRS of LAQ824-treated tumor extracts also
showed significant decreases in GPE and GPC and increased choline
levels. These phospholipid changes have also been observed after
treatment of HT29 tumors with the vascular disruptive agent, 5,6-
dimethylxanthenone-4-acetic acid [54]. Choline-containing metabo-
lites are associated with membrane metabolism, and changes in the
concentration of these metabolites may indicate changes in membrane
turnover. The significant drop in GPC and GPE (membrane degrada-
tion products) and significant rise in free choline (not membrane-
bound) after LAQ824 treatment suggests that LAQ824 may cause a
reduction in membrane turnover and thus growth inhibition.
An increase in branched-chain amino acids (i.e., leucine, iso-leucine,
and valine) was observed in 1H MRS of LAQ824-treated tumor ex-
tracts. This observation suggests a reduction in protein synthesis in
HT29 tumors after treatment. Therefore, the vascular effects induced
by LAQ824 cause severe disruption of essential nutrients being trans-
ported to the tumor, which then induces a depletion of energy within
the tumor and leads to a decrease in tumor growth.
The impairment in tumor bioenergetics and many metabolic
changes observed in tumor extracts are not observed in vitro, in cell
studies. This is consistent with the hypothesis that these changes are
likely to be linked to the vascular effects of LAQ824 on solid tumors
[25]. Cultured tumor cells are bathed in well-oxygenated medium con-
taining sufficient levels of nutrients, whereas, in vivo, the structurally
and functionally disturbed microcirculation is likely to impair the de-
livery of nutrients and oxygen [57,58]. This could lead to dysfunctional
energy metabolism manifested by decreases in tumor bioenergetics.
In conclusion, the present study has identified two potential non-
invasive surrogate biomarkers for the action of LAQ824: (1) a decrease
in tumor bioenergetics and (2) an increase in PME. Similar effects of
LAQ824 on PC and PME levels were found to occur in cultured cells
in vitro, in tumor xenografts in vivo, and in tumor extracts in vitro.
The increased PME/TotP ratio, which was only observed in vivo,
was found to correlate with tumor response, indicating that it could
act as a potential pharmacodynamic biomarker of drug activity. Hence,
monitoring the pharmacodynamic effects of LAQ824 treatment and
possibly of other HDAC inhibitors on tumor phospholipid metabo-
lism by 31P MRS may provide noninvasive surrogate markers for
HDAC inhibition and potentially of response in solid tumors in clini-
cal trials.
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